Last reviewed · How we verify
paclitaxel plus trastuzumab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
paclitaxel plus trastuzumab (paclitaxel plus trastuzumab) — WiSP Wissenschaftlicher Service Pharma GmbH.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| paclitaxel plus trastuzumab TARGET | paclitaxel plus trastuzumab | WiSP Wissenschaftlicher Service Pharma GmbH | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- paclitaxel plus trastuzumab CI watch — RSS
- paclitaxel plus trastuzumab CI watch — Atom
- paclitaxel plus trastuzumab CI watch — JSON
- paclitaxel plus trastuzumab alone — RSS
Cite this brief
Drug Landscape (2026). paclitaxel plus trastuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-plus-trastuzumab. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab